Immuron Ltd: peers
Immuron Ltd beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Immuron Ltd, Memphasys Limited, Vectus Biosystems Limited, Medlab Clinical Limited, Acrux Limited, Bio-Gene Technology Limited, AdAlta Limited: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Immuron Ltdbase IMRN · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Propanc Biopharma, Inc. PPCB · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Memphasys Limited MEM.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Vectus Biosystems Limited VBS.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Medlab Clinical Limited MDC.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Acrux Limited ACR.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Bio-Gene Technology Limited BGT.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | AdAlta Limited 1AD.AX · 🇦🇺 AU Percentile in Healthcare Percentile in Australia | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $9 MAug 1, 2026 · Market data5th of 8 | $13 MOct 29, 2026 · Market data1st of 8 | $9 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one5th of 8 | $10 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $10 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one2nd of 8 | $10 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $8 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $8 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $10 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $5 MFY2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | —— | $5 M— |
| Net income (Higher is better) | $-3 MFY2025 · SEC1st of 2 | $-19 MFY2026 · SEC2nd of 2 | —— | —— | —— | —— | —— | —— | $-11 M2 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | +47.0%FY2025 · SEConly one with it83rd72nd | ———— | ———— | ———— | ———— | ———— | ———— | ———— | +47.0%— |
| Revenue growth, 3 years a year (Higher is better) | +103.5%FY2025 · SEConly one with it95th95th | ———— | ———— | ———— | ———— | ———— | ———— | ———— | +103.5%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 65.5%FY2025 · SEConly one with it60th— | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 65.5%— |
| Operating margin (Higher is better) | -73.3%FY2025 · SEConly one with it26th— | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -73.3%— |
| Net margin (Higher is better) | -71.6%FY2025 · SEConly one with it27th38th | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -71.6%— |
| Return on equity (Higher is better) | -49.2%FY2025 · SEC1st of 244th32nd | -161.8%FY2026 · SEC2nd of 214th2nd | ———— | ———— | ———— | ———— | ———— | ———— | -105.5%2 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | 1.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | ———— | ———— | ———— | ———— | —— |
| Price to book (Better neither way: ranked highest first) | 1.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 1.4×price Oct 29, 2026 · Market dataonly one with it28th— | ———— | ———— | ———— | ———— | ———— | ———— | 1.4×— |
| Free cash flow yield (Higher is better) | -42.8%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -42.5%price Oct 29, 2026 · Market dataonly one with it21st— | ———— | ———— | ———— | ———— | ———— | ———— | -42.5%— |
| Financial strength | |||||||||
| Interest cover (Higher is better) | ———— | -42.3×FY2026 · SEConly one with it23rd— | ———— | ———— | ———— | ———— | ———— | ———— | -42.3×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 7 of 15FY2025 · Scorecard1st of 2 | 2 of 12FY2026 · Scorecard2nd of 2 | —— | —— | —— | —— | —— | —— | 32% passed2 ranked |
| Valuation checks (Higher is better) | —— | 1 of 4FY2026 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 25% passed— |
| Growth checks (Higher is better) | 4 of 6FY2025 · Scorecard1st of 2 | 0 of 2FY2026 · Scorecard2nd of 2 | —— | —— | —— | —— | —— | —— | 33% passed2 ranked |
| Profitability checks (Higher is better) | 1 of 5FY2025 · Scorecard1st of 2 | 0 of 3FY2026 · Scorecard2nd of 2 | —— | —— | —— | —— | —— | —— | 10% passed2 ranked |
| Financial health checks (Higher is better) | 1 of 3FY2025 · Scorecard1st of 2 | 1 of 3FY2026 · Scorecard1st of 2 | —— | —— | —— | —— | —— | —— | 33% passed2 ranked |
| Shareholder returns checks (Higher is better) | 1 of 1FY2025 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | —— | 100% passed— |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 1.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 1.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | —— | —— | —— | 1.6%2 ranked |
| Institutions holding (Better neither way: ranked highest first) | 82026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | 52026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | —— | —— | —— | 72 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Immuron Ltd: How market caps are worked out; Propanc Biopharma, Inc.: How market caps are worked out; Memphasys Limited: How market caps are worked out; Vectus Biosystems Limited: How market caps are worked out; Medlab Clinical Limited: How market caps are worked out; Acrux Limited: How market caps are worked out; Bio-Gene Technology Limited: How market caps are worked out; AdAlta Limited: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Immuron Ltd | -73.3%FY2025 | 26th percentile in Healthcaremedian -7.7%, 674 companies | — |
| Propanc Biopharma, Inc. | — | — | — |
| Memphasys Limited | — | — | — |
| Vectus Biosystems Limited | — | — | — |
| Medlab Clinical Limited | — | — | — |
| Acrux Limited | — | — | — |
| Bio-Gene Technology Limited | — | — | — |
| AdAlta Limited | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | Immuron Ltd | Propanc Biopharma, Inc. | Memphasys Limited | Vectus Biosystems Limited | Medlab Clinical Limited | Acrux Limited | Bio-Gene Technology Limited | AdAlta Limited |
|---|---|---|---|---|---|---|---|---|
| 2025 | $5 MSEC | — | — | — | — | — | — | — |
| 2024 | $3 MSEC | — | — | — | — | — | — | — |
| 2023 | $1 MSEC | — | — | — | — | — | — | — |
| 2022 | $1 MSEC | — | — | — | — | — | — | — |
| 2021 | $0 MSEC | — | — | — | — | — | — | — |
| 2020 | $2 MSEC | — | — | — | — | — | — | — |
| 2019 | $1 MSEC | — | — | — | — | — | — | — |
| 2018 | $1 MSEC | — | — | — | — | — | — | — |
| 2017 | $1 MSEC | — | — | — | — | — | — | — |
| 2016 | $1 MSEC | — | — | — | — | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Immuron Ltd#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Propanc Biopharma, Inc.PPCB · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $13 M market cap against $9 M · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $13 M (Oct 29, 2026)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Memphasys LimitedMEM.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $9 M market cap against $9 M · Same country: AustraliaMarket cap $9 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Vectus Biosystems LimitedVBS.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $10 M market cap against $9 M · Same country: AustraliaMarket cap $10 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Medlab Clinical LimitedMDC.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $10 M market cap against $9 M · Same country: AustraliaMarket cap $10 M (last known, Dec 25, 2022)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Acrux LimitedACR.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $10 M market cap against $9 M · Same country: AustraliaMarket cap $10 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Bio-Gene Technology LimitedBGT.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $8 M market cap against $9 M · Same country: AustraliaMarket cap $8 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- AdAlta Limited1AD.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $8 M market cap against $9 M · Same country: AustraliaMarket cap $8 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Benitec Biopharma Inc.BNTC · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $8 M market cap against $9 M · Same country: AustraliaMarket cap $8 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)+ Add
- Radiopharm Theranostics LimitedRAD.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $23 M market cap against $9 M · Same country: Australia · Ratios of the last two fiscal years on fileMarket cap $23 M (last known, Jan 5, 2024) · revenue $4 M (year to June 2025)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)+ Add
- Bionomics LimitedBNOX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $11 M market cap against $9 M · Same country: AustraliaMarket cap $11 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)+ Add
- Amplia Therapeutics LimitedATX.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $11 M market cap against $9 M · Same country: AustraliaMarket cap $11 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)+ Add
- Patrys LimitedPAB.AX · 🇦🇺 AustraliaSame industry: Biotechnology · Similar size: $11 M market cap against $9 M · Same country: AustraliaMarket cap $11 M (last known, Jan 5, 2024)94 of 100 (industry or sector 50 + size 29 + country 15)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.